Equity Overview
Price & Market Data
Price: $2.04
Daily Change: $0.00 / 0.00%
Daily Range: $1.66 - $2.17
Market Cap: $6,037,316
Daily Volume: 180,852
Performance Metrics
1 Week: 8.51%
1 Month: -61.22%
3 Months: -24.72%
6 Months: -52.11%
1 Year: -80.28%
YTD: -24.72%
Company Details
Employees: 15
Sector: Health technology
Industry: Medical specialties
Country: United States
Details
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.